Oxurion & Bicycle Therapeutics declare full enrollment for DME study
Category: #health  By Nikita Chaurasia  Date: 2019-04-26
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Oxurion & Bicycle Therapeutics declare full enrollment for DME study

Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase I clinical trial planned to assess the safety of THR-149’s single injection. The injection essentially is a new Bicycle-based plasma kallikrein suppressor.

According to a press release by the Bicycle Therapeutics, the agreement states that Oxurion has exclusive authority to conduct clinical and preclinical development, as well as commercialization of a designated medicine candidate. In return, Bicycle would attain milestone payments for development and royalties on sales of products resulting from the association.

Bicycle provides a differentiated method to a variety of debilitating ailments, and the company is pleased to view the growth Oxurion has attained in successfully finishing the registration of the Phase I study of the first Bicycle-based therapeutic, stated Kevin Lee, Ph.D., CEO Bicycle Therapeutics.

THR-149, in consort with Bicycle-owned BT1718, Bicycle Toxin Conjugate for oncology, represents the first of many initiatives the firm is proceeding with to bring this exceptional therapeutic modality to patients with significant unfulfilled medical needs, Lee added.

Patrik De Haes, M.D. & CEO of Oxurion, reportedly stated that patients suffering from diabetic macular edema have higher levels of PKal. Our aim in the current Phase I clinical trial is to assess the safety of a single THR-149 intravitreal injection, a new Bicycle-based PKal suppressor, in patients having visual impairment because of diabetic macular edema, Haes stated. Enrolling subjects is the first step to assessing whether we can constrain PKal with Bicycle’s new bicyclic peptides, he added.

For the record, Bicycle Therapeutics is a clinical-phase biopharmaceutical firm developing a new class of pills, termed as Bicycles, for illnesses that are underserved by currently available therapeutics. It was founded in 2009, resulting from an innovative science performed by Professor Christian Heinis and Sir Greg Winter.

Source Credits: https://www.apnews.com/Business%20Wire/2aec99859114480da690c30619ccc460

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

By Nikita Chaurasia

Scientists from the U.S. Food and Drug Administration (FDA) claimed that Moderna did not meet all the requirements to support the use of COVID-19 booster shots. This is because the first two shots already showed a strong efficacy rate. Documents rel...

Canada’s healthcare sector likely to brace for looming staff shortages

Canada’s healthcare sector likely to brace for looming staff shortages

By Nikita Chaurasia

According to reliable sources, Canada’s overworked healthcare sector is now bracing for upcoming staff shortages and potential layoffs, as the country accelerates its vaccination drive before the deadline. The development comes at a time when l...

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

By Nikita Chaurasia

The space industry is booming as new companies with fresh ideas for space-based applications take advantage of declining launch and satellite costs. Out of those firms, Rocket Lab USA bagged a contract to launch 25 satellites on five missions exclusi...